



LRI Children's Hospital

Guidance for the prevention and management of overgranulation

at gastrostomy and jejunostomy stomas

Staff relevant to:	UHL Children's Hospital nursing and medical staff caring for infants and children with gastrostomy and jejunostomy devices
Team approval date:	November 2022
Version:	1
Revision due:	November 2024
Written by:	S Caldwell
Trust Ref:	C64/2022

1. Introduction and Who Guideline applies to


This Guidance is applicable to all levels of nursing and medical staff caring for infants and children with gastrostomy and jejunostomy devices. The purpose of this document is to guide staff in the prevention and management of overgranulation tissue around gastrostomy and jejunostomy devices.

Overgranulation Definition - A nodule of excess granulation tissue at the gastrostomy or jejunostomy insertion site which occurs due to inflammatory and immune responses and can be further complicated by friction and moisture. (Remington and Simons 2013, Borkowski 2005)


2. Identification and management of granulation

The following two tables provide information on the grading (normal, mild, moderate and severe), investigations, treatment and ongoing management of stoma site overgranulation.

Page 1 of 5



Treatment of skin infections



If no improvement or patient becomes systemically unwell: seek medical advice (i.e. to rule out sepsis) and for further management

improvement

or gets

worse with

topical then

consider oral

antibiotics

(MSSA/MRSA)

Moderate to severe erythema,

tracking +/- pus

Wound swab for

culture &

sensitivity-start

Oral antibiotics +

topical treatment

(as indicated by

previous swab

result) *

See - Sepsis UHL Childrens Hospital Guideline

Title: Prevention and management of overgranualtion at gastrostomy and jejunostomy stoma's

V: 2 Approved by Children's Clinical Practice Group on: November 2022 Trust Ref: C64/2022 Next Review: November 2024 NB: Paper copies of this document may not be most recent version. The definitive version is held on InSite in the Policies and Guidelines Library

Antifungal cream

used to treat fungal infections, i.e. Clotrimazole, Daktacort Miconazole.

NB - Daktacort is a combination product of both Miconazole and Hydrocortisone

Dexamethasone, Neomycin, Polymyxin b

i.e. Maxitrol eye ointment, containing antibiotic and steroidal properties

Fusidic acid and hydrocortisone acetate i.e., Fucidin H cream

lodine an antiseptic that kills bacteria and pathogens for example, Inadine, Povitulle

Silicone adhesive foam dressing

i.e., Allevyn Gentle Border, Kiliderm, Mepliex Border Lite

Silver sulphadiazine

(SSD) is a sulphonamide that kills bacteria by working on the cell membrane and cell wall i.e., Urgotul SSD

Oral Antibiotics

Please see BNF for prescribing guidance and dose. https://bnfc.nice.org.uk/

2.1 Special Considerations

- *Do not apply iodine dressing to children under 6 months old, or if they have renal problems.
- Obtain swab for culture & sensitivity if infection suspected. Treat infection as indicated by microbiology results.
- If there are no previous microbiology result and oral antibiotics are required, start oral flucloxacillin (if intolerant to oral flucloxacillin-oral cefalexin; penicillin allergy- oral clarithromycin) after taking swab for culture & sensitivity.
- Oral antibiotics:
 - First line- oral flucloxacillin (oral solution can be unpalatable, use capsules if able to swallow)
 - If intolerant to oral flucloxacillin oral cefalexin
 - Penicillin allergy oral clarithromycin
- Contact microbiology for treatment options if evidence of infection and patient is known to have MRSA in the past or currently growing MRSA from the swab culture.
- Consider MRSA decolonisation for patients who isolate MRSA on swabs.
- Coliforms from stoma site swabs usually represent colonisation and would not require treatment.
- PEG device may require to be surgically removed if recurrent problems with gastrostomy site. Liaise with Gastrostomy Nurse and patient's surgical consultant.
- If using creams or ointments containing steroids, apply a thin layer and wash hands immediately post

3. Education and Training

None

4. Monitoring Compliance

None identified

5. Supporting References

C Gardiner, A Rodgers, L Paterson & M Kinney, Network Manager with support from WoSPGHaN Enteral Nutrition sub-group Published: January 2019 (Version 1)

Remington and Simons 2013, The percutaneous endoscopic gastrostomy tube: a nurse's guide to PEG tubes Medsurg Nurs. Mar-Apr 2013;22(2):77-83.

S. Borkowski 2005. G tube care: managing hypergranulation tissue. Nursing. 2005 Aug;35(8):24.

6. Key Words

PEG, Tissue

The Trust recognises the diversity of the local community it serves. Our aim therefore is to provide a safe environment free from discrimination and treat all individuals fairly with dignity and appropriately according to their needs. As part of its development, this policy and its impact on equality have been reviewed and no detriment was identified.

CONTACT AND REVIEW DETAILS			
Guideline Lead (Name and Title)	Executive Lead		
S Caldwell – Nurse Specialist	Chief Nurse		
Details of Changes made during review:			
New document			
V2 January 2023			
Typo in severe treatment on page 2 - corrected Did say Adhere to mild treatment regime now			
states moderate			
Removed fluconazole cream as not an available			
Removed Nystatin oral liquid as treatment consideration			
Clarified that Daktacort is a combination product of miconazole and hydrocortisone.			
Added MRSA decolonisation for patients who isolate MRSA on swabs.			
Removed Nystaform HC as its non-formulary			

Page 5 of 5